US Edition
News from Pharmaceutical Business review
Information about Pharmaceutical Business Review
Where is Pharmaceutical Business Review located?Pharmaceutical Business Review's WebsiteMedia Bias Ratings
Do you diasgree?
Edit bias
Learn more about Media Bias Ratings.
Factuality
Learn more about Factuality Ratings
Reveal Factuality Ratings by upgrading to a Premium account.
Tap Upgrade to explore subscription options to meet all your reading needs.
Ownership
Learn more about Ownership categories
Reveal Ownership Data by upgrading to a Vantage account.
Tap Upgrade to explore subscription options to meet all your reading needs.
Top Pharmaceutical Business Review News
TechnologyHYDERABAD, India and REYKJAVIK, Iceland, June 05, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide (“Alvotech”), and Dr. Reddy’s Laboratories Ltd., (BSE: 500124See the Story
Alvotech and Dr. Reddy’s Enter into Collaboration to Co-Develop Biosimilar Candidate to ...
43% Right coverage: 7 sources
United States · United StatesAlcon (SIX/NYSE: ALC), the global leader in eye care dedicated to helping people see brilliantly, today announced the U.S. Food and Drug Administration (FDA) has approved TRYPTYR® (acoltremon ophthalmic solution) 0.003%, formerly known as AR-15512, for the treatment of signs and symptoms of Dry Eye Disease (DED).3 TRYPTYR is a first-in-class TRPM8 receptor agonist (neuromodulator) that stimulates […]See the Story
Alcon Announces FDA Approval of TRYPTYR (Acoltremon Ophthalmic Solution) 0.003% for the Treatment of the Signs and Symptoms of Dry Eye Disease
67% Center coverage: 3 sources
Eli LillyEli Lilly is partnering with Camurus, a company with technology that extends how long an injectable drug lasts in the body, permitting longer dosing intervals. Lilly plans to apply the technology to its metabolic medicines; the deal follows a similar move Novo Nordisk starting an alliance with Ascendis. The post Following Novo Nordisk, Eli Lilly Lands Partner for R&D of Longer-Acting Metabolic Meds appeared first on MedCity News.See the Story
Following Novo Nordisk, Eli Lilly Lands Partner for R&D of Longer-Acting Metabolic Meds
100% Center coverage: 2 sources
